Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C31H39ClN2O8 |
| Molecular Weight | 603.103 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC=CC([C@H]2O[C@H](CC(=O)N3CCC(CC(O)=O)CC3)C(=O)N(CC(C)(C)CO)C4=C2C=C(Cl)C=C4)=C1OC
InChI
InChIKey=HDGUKVZPMPJBFK-LEAFIULHSA-N
InChI=1S/C31H39ClN2O8/c1-31(2,18-35)17-34-23-9-8-20(32)15-22(23)28(21-6-5-7-24(40-3)29(21)41-4)42-25(30(34)39)16-26(36)33-12-10-19(11-13-33)14-27(37)38/h5-9,15,19,25,28,35H,10-14,16-18H2,1-4H3,(H,37,38)/t25-,28-/m1/s1
| Molecular Formula | C31H39ClN2O8 |
| Molecular Weight | 603.103 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Lapaquistat acetate: development of a squalene synthase inhibitor for the treatment of hypercholesterolemia. | 2011-05-10 |
|
| Squalene synthase inhibition: a novel target for the management of dyslipidemia. | 2007-01 |
|
| Lipid-lowering properties of TAK-475, a squalene synthase inhibitor, in vivo and in vitro. | 2003-07 |
|
| Synthesis of novel 4,1-benzoxazepine derivatives as squalene synthase inhibitors and their inhibition of cholesterol synthesis. | 2002-09-26 |
Patents
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 19:40:50 GMT 2025
by
admin
on
Mon Mar 31 19:40:50 GMT 2025
|
| Record UNII |
PEZ79BV72X
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C29703
Created by
admin on Mon Mar 31 19:40:50 GMT 2025 , Edited by admin on Mon Mar 31 19:40:50 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C96287
Created by
admin on Mon Mar 31 19:40:50 GMT 2025 , Edited by admin on Mon Mar 31 19:40:50 GMT 2025
|
PRIMARY | |||
|
DTXSID80172294
Created by
admin on Mon Mar 31 19:40:50 GMT 2025 , Edited by admin on Mon Mar 31 19:40:50 GMT 2025
|
PRIMARY | |||
|
8662
Created by
admin on Mon Mar 31 19:40:50 GMT 2025 , Edited by admin on Mon Mar 31 19:40:50 GMT 2025
|
PRIMARY | |||
|
PEZ79BV72X
Created by
admin on Mon Mar 31 19:40:50 GMT 2025 , Edited by admin on Mon Mar 31 19:40:50 GMT 2025
|
PRIMARY | |||
|
300000036999
Created by
admin on Mon Mar 31 19:40:50 GMT 2025 , Edited by admin on Mon Mar 31 19:40:50 GMT 2025
|
PRIMARY | |||
|
LAPAQUISTAT
Created by
admin on Mon Mar 31 19:40:50 GMT 2025 , Edited by admin on Mon Mar 31 19:40:50 GMT 2025
|
PRIMARY | |||
|
9960389
Created by
admin on Mon Mar 31 19:40:50 GMT 2025 , Edited by admin on Mon Mar 31 19:40:50 GMT 2025
|
PRIMARY | |||
|
189059-71-0
Created by
admin on Mon Mar 31 19:40:50 GMT 2025 , Edited by admin on Mon Mar 31 19:40:50 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> INHIBITOR |
In differentiated RD cells inhibition of cholesterol synthesis.
IC50
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> METABOLITE ACTIVE |
In RD cells inhibited cholesterol biosynthesis
IC50
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Effective at lowering low-density lipoprotein cholesterol in a dose-dependent manner, development of the drug was ceased due to observations in clinical trials that it might cause liver damage
|